Similarly, the administration of recombinant TRAIL or adenoviral TRAIL resulted in a significant reduction in cardiac fibrosis and apoptosis compared to control diabetic animals [76], and MD5-1 (agonistic mDR5 mAb) treatment to wildtype mice resulted in increased heart weight and cardiomyocyte area, in part through the activation of the epidermal growth factor receptor [75]. This evidence concerns the gene TNFSF10 and fibrosis.